Supreme Court favors Teva; implications go beyond Copaxone
This article was originally published in Scrip
Executive Summary
The US Supreme Court on 20 January sided with Israeli drug maker Teva in a lawsuit involving the firm's money-maker drug Copaxone (glatiramer acetate), with the justices declaring an appeals court had failed to use the proper standard when it invalidated the company's last remaining patent on the multiple sclerosis medicine.